Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alvotech ( (ALVO) ) just unveiled an update.
Alvotech, a global biotech group specializing in biosimilar medicines and backed by a fully integrated development and manufacturing platform, has built a portfolio of five marketed biosimilars and a pipeline of nine disclosed candidates aimed at major chronic and specialty disease areas. The company reaches key geographies such as the U.S., Europe, Japan, China and emerging markets through a network of strategic commercial partnerships.
On April 30, 2026, Alvotech reported a change in its executive ranks, announcing that General Counsel Tanya Zharov has asked to step down after six years with the company. Zharov, who played a central role in preparing Alvotech for multiple public listings and attracting international talent to Reykjavik, will remain for several months to support an orderly handover while continuing to work with chairman Róbert Wessman via board roles at his holding companies, underscoring continuity in the firm’s broader governance circle.
The most recent analyst rating on (ALVO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
The score is primarily constrained by elevated financial risk (high and rising debt, negative equity, and weak cash-flow history) and a bearish technical setup. Earnings call guidance and operational progress provide partial support, but regulatory timing risk in the U.S. and a high P/E keep the overall score in the mid-range.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotechnology company founded by Robert Wessman and focused exclusively on developing and manufacturing biosimilar medicines. The company markets five approved biosimilars, including versions of Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, and is advancing a pipeline of nine additional candidates targeting autoimmune, eye, bone, respiratory and oncology indications across major markets worldwide.
Average Trading Volume: 553,462
Technical Sentiment Signal: Sell
Current Market Cap: $1.08B
See more data about ALVO stock on TipRanks’ Stock Analysis page.